Acute Myeloid Leukemia (AML) is a fast-progressing cancer of the blood and bone marrow, characterized by the abnormal proliferation of myeloid cells. These cancerous cells hinder the production of healthy blood cells, leading to anemia, infections, and bleeding complications. AML primarily affects older adults, with a higher incidence in individuals over 60 years. It is the most common type of acute leukemia in adults, accounting for about 1% of all cancers globally. The disease progresses rapidly, requiring immediate medical attention. Despite advancements in chemotherapy, stem cell transplants, and targeted therapies, AML remains challenging to treat due to high relapse rates. Early diagnosis and personalized treatment approaches are crucial for improving patient outcomes.
